Krsnaa Diagnostics Limited (NSE:KRSNAA)
India · Delayed Price · Currency is INR | Market Cap | 16.39B -30.2% |
| Revenue (ttm) | 8.86B +16.6% |
| Net Income | 981.04M +16.0% |
| EPS | 29.96 +16.7% |
| Shares Out | 32.44M |
| PE Ratio | 16.87 |
| Forward PE | 14.03 |
| Dividend | 2.00 (0.40%) |
| Ex-Dividend Date | Sep 18, 2026 |
| Volume | 48,379 |
| Open | 493.65 |
| Previous Close | 493.60 |
| Day's Range | 490.60 - 506.95 |
| 52-Week Range | 463.10 - 838.00 |
| Beta | 0.08 |
| Analysts | Buy |
| Price Target | 819.75 (+62.2%) |
| Earnings Date | Nov 2, 2026 |
About Krsnaa Diagnostics
Krsnaa Diagnostics Limited provides diagnostic services in India. It offers mammography, stress tests, dual-energy X-ray absorptiometry scans, bone mineral density tests, computed tomography scans, and magnetic resonance imaging services, as well as tele-radiology and tele-pathology services. The company was incorporated in 2010 and is based in Pune, India. [Read more]
Financial Performance
In fiscal year 2026, Krsnaa Diagnostics's revenue was 7.73 billion, an increase of 7.75% compared to the previous year's 7.17 billion. Earnings were 1.01 billion, an increase of 30.70%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for KRSNAA stock is "Buy." The 12-month stock price target is ₹819.75, which is an increase of 62.20% from the latest price.
News
Krsnaa Diagnostics Transcript: Q2 26/27
H1 FY27 revenue rose 27% to INR 507 crore, while higher implementation, depreciation and financing costs pressured margins and PAT. Cash-based projects, retail growth and collections are central to improving cash flow and returns.
Krsnaa Diagnostics Quarterly report: Q2 2027
Krsnaa Diagnostics has published its Q2 2027 quarterly earnings report on November 3, 2026.
Krsnaa Diagnostics Slides: Q2 2027
Krsnaa Diagnostics has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 3, 2026.
Krsnaa Diagnostics Transcript: Q1 26/27
Revenue grew 22% YoY in Q1 FY27, with retail business up 64% and major PPP wins boosting long-term visibility. Margins were impacted by upfront costs, but are expected to improve as new projects mature and retail contribution rises to 10–15% of revenue.
Krsnaa Diagnostics Quarterly report: Q1 2027
Krsnaa Diagnostics has published its Q1 2027 quarterly earnings report on August 14, 2026.
Krsnaa Diagnostics Slides: Q1 2027
Krsnaa Diagnostics has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 14, 2026.
Krsnaa Diagnostics Transcript: Q4 25/26
FY 2026 saw revenue of INR 7,728 million, EBITDA margin of 28%, and PAT of INR 1,014 million, with strong growth in retail and major PPP expansion in Rajasthan. Receivables improved, CapEx of INR 5,000 million planned, and EBITDA margins are expected to be maintained.
Krsnaa Diagnostics Quarterly report: Q4 2026
Krsnaa Diagnostics has published its Q4 2026 quarterly earnings report on May 26, 2026.
Krsnaa Diagnostics Slides: Q4 2026
Krsnaa Diagnostics has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 26, 2026.
Krsnaa Diagnostics Annual report: Q4 2026
Krsnaa Diagnostics has published its Q4 2026 annual report on May 26, 2026.
Krsnaa Diagnostics Transcript: Q3 25/26
Q3 FY26 saw modest 4% revenue growth, strong cash recovery, and resilient margins despite seasonality and expansion costs. Retail revenue surged 8x year-over-year, and the Rajasthan project is set to drive significant growth by FY27.
Krsnaa Diagnostics Quarterly report: Q3 2026
Krsnaa Diagnostics has published its Q3 2026 quarterly earnings report on February 6, 2026.
Krsnaa Diagnostics Slides: Q3 2026
Krsnaa Diagnostics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 6, 2026.
Why are Krsnaa Diagnostics shares down 3% today? Explained
Shares of Krsnaa Diagnostics were trading lower on Thursday, February 6, after the company reported a mixed set of Q3...
Krsnaa Diagnostics approves Rs 430 crore fundraise via NCDs
Krsnaa Diagnostics has announced that its Board of Directors has approved the issuance of unlisted, secured, redeemable, and transferable non-convertible...
Krsnaa Diagnostics Transcript: Q2 25/26
Q2 FY26 saw 11% revenue growth and 18% EBITDA growth, with margins expanding to 29%. Retail business surged 60% quarter-on-quarter and is expected to reach 15-20% of revenue next year. Major PPP projects and retail expansion are set to drive future growth.
Krsnaa Diagnostics Quarterly report: Q2 2026
Krsnaa Diagnostics has published its Q2 2026 quarterly earnings report on November 9, 2025.
Krsnaa Diagnostics Slides: Q2 2026
Krsnaa Diagnostics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 9, 2025.
Krsnaa Diagnostics shares jump over 3% as Q2 revenue rises 10.5% YoY to Rs 206 crore, net profit rose 21.9%
Krsnaa Diagnostics shares gained over 3% in early trade on Monday after the company posted a healthy set of numbers...
Krsnaa Diagnostics Earnings Call Transcript: Q1 2026
Q1 FY 2026 saw 13% revenue growth, 19% EBITDA growth, and 15% PAT growth, with retail revenue rising to 6% of total. The Rajasthan PPP contract expands scale, with full rollout in 6-9 months and material revenues from FY 2027. Margins and working capital remain strong.
Krsnaa Diagnostics Quarterly report: Q1 2026
Krsnaa Diagnostics has published its Q1 2026 quarterly earnings report on August 12, 2025.
Krsnaa Diagnostics Slides: Q1 2026
Krsnaa Diagnostics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 12, 2025.
Krsnaa Diagnostics shares fall over 3% following Q1 results
Shares of Krsnaa Diagnostics Limited dropped 3.58% to Rs 836.05 on Tuesday, August 12, despite the company reporting strong financial performance for the first quarter of FY26. The decline is likely d...
Krsnaa Diagnostics gets Rajasthan High Court nod, to proceed with NHM lab services contract
Krsnaa Diagnostics Limited announced on Monday, July 7, that it has received a fresh Letter of Acceptance (LoA) from the National Health Mission (NHM), Rajasthan, to provide laboratory services under ...
Krsnaa Diagnostics Transcript: Q4 24/25
Revenue grew 16% year-on-year to INR 7,172 million in FY 2025, with EBITDA up 34% and net profit up 37%. Retail diagnostics expanded rapidly, and margins improved to 27%. Receivable days are targeted to reduce, and asset-light expansion will keep CapEx low.